Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy

Helen H.W. Chen, Wen Chung Chen, Zhang Dong Liang, Wen Bin Tsai, Yan Long, Isamu Aiba, Siqing Fu, Russell Broaddus, Jinsong Liu, Lynn G. Feun, Niramol Savaraj, Macus Tien Kuo

研究成果: Review article同行評審

28 引文 斯高帕斯(Scopus)


Introduction: Platinum (Pt)-based antitumor agents remain important chemotherapeutic agents for treating many human malignancies. Elevated expression of the human high-affinity copper transporter 1 (hCtr1), resulting in enhanced Pt drug transport into cells, has been shown to be associated with improved treatment efficacy. Thus, targeting hCtr1 upregulation is an attractive strategy for improving the treatment efficacy of Pt-based cancer chemotherapy.Area covered: Regulation of hCtr1 expression by cellular copper homeostasis is discussed. Association of elevated hCtr1 expression with intrinsic sensitivity of ovarian cancer to Pt drugs is presented. Mechanism of copper-lowering agents in enhancing hCtr1-mediated cis-diamminedichloroplatinum (II) (cisplatin, cDDP) transport is reviewed. Applications of copper chelation strategy in overcoming cDDP resistance through enhanced hCtr1 expression are evaluated.Expert opinion: While both transcriptional and post-translational mechanisms of hCtr1 regulation by cellular copper bioavailability have been proposed, detailed molecular insights into hCtr1 regulation by copper homeostasis remain needed. Recent clinical study using a copper-lowering agent in enhancing hCtr1-mediated drug transport has achieved incremental improvement in overcoming Pt drug resistance. Further improvements in identifying predictive measures in the subpopulation of patients that can benefit from the treatment are needed.

頁(從 - 到)1307-1317
期刊Expert Opinion on Therapeutic Targets
出版狀態Published - 2015 10月 3

All Science Journal Classification (ASJC) codes

  • 分子醫學
  • 藥理
  • 藥物發現
  • 臨床生物化學


深入研究「Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy」主題。共同形成了獨特的指紋。